All In MedTech

Device Trial Radar · NCT06520124

Stellest Lens Wear in Adult Progressing Myopes

Effectiveness of Essilor® Stellest® Lenses in Slowing Down Myopia Progression in Young Adults

Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Oct 17, 2024

Primary completion

Dec 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
University of UlsterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Essilor International
First posted
Jul 25, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

It is expected that myopia progression stabilises in the late teenage years, however, some studies report that myopia progression continues through early adulthood in as many as one third of myopes. Similarly, there are reports of myopia commencing in early adulthood. Although the rate of progression is slower than that occurring in childhood, between 20-35% of adults aged between 20-30 years were reported to progress by at least -1.00D over a five year period. Given that every dioptre increase in myopia results in an increased overall lifetime risk of serious ocular pathology, it seems opportune to investigate whether myopia management treatments designed to slow myopia progression in childhood could be beneficial for progressing adult myopes. The proposed study will conduct a prospective, randomised, paired-eye, trial with cross-over to evaluate the efficacy of Essilor Stellest myopia management spectacle lenses on the progression of myopia in adults aged between 18-40 years. The outcomes from the trial will provide novel evidence regarding the utility of these lenses in an adult population.

Conditions

  • Myopia, Progressive

Interventions

  • Essilor® Stellest® spectacle lensDevice

    Spectacle lens with highly aspherical lenslets.

  • Single-vision spectacle lensDevice

    Standard single-vision distance spectacle lens.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in axial length (mm)Time frame: 2 years
  2. Change in cycloplegic autorefraction (D)Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ulster University

    Coleraine, County Londonderry, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.